Report Code : CVMI1305202506 | Published Date : May 13, 2025

1. Market Overview

The global animal CRISPR therapeutics market is projected to grow from USD 2.4 billion in 2026 to USD 9.8 billion by 2031, at a 32.1% CAGR, driven by single-dose cures for genetic diseases and USDA fast-track approvals.

Market Segmentation

  1. By Application
    • Monogenic Disorders (45% share):
      • Canine Duchenne muscular dystrophy (DMD) therapy
      • Feline polycystic kidney disease (PKD) cure
    • Oncology (XX%):
      • CAR-T cell editing for canine lymphoma
    • Infectious Disease (XX%):
      • FIV-resistant cats via CCR5 gene knockout
  2. By Animal Type
    • Companion Animals (XX% revenue):
      • Dogs (XX%), cats (XX%), horses (10%)
    • Livestock (XX%):
      • PRRS-resistant pigs (commercialized 2025)
  3. By Delivery System
    • AAV Vectors (XX%)
    • Lipid Nanoparticles (30%)
    • Electroporation (XX%)

2. Key Growth Drivers

1. Clinical Efficacy Breakthroughs

  • Canine DMD Trial:
    • 80% dystrophin restoration at 12 months (UC Davis)
  • Feline PKD Cure:
    • Stops cyst growth with single injection (CRISPR Tx)

2. Regulatory Acceleration

  • USDA's 2025 Gene Edit Policy:
    • Exempts single-base edits from GMO regulation
  • FDA Center of Excellence:
    • 6-month review pathway for veterinary gene therapies

3. Economic Viability

  • One-Time Treatment:
    • 15,000 cost vs. 15,000 cost vs. 5,000/year for chronic management
  • Breeder Adoption:
    • Champion lines preserve genetics with edited offspring

3. Competitive Landscape

Company

Breakthrough

Market Impact

CRISPR Tx

Feline PKD cure

70% market share

Rejuvenate Bio

Canine DMD therapy

$1.2B valuation

Genus PIC

PRRS-resistant pigs

100K animals edited

4. Future Outlook (2026-2031)

  • 2027: First FDA-approved CRISPR product (canine DMD)
  • 2029: Germline editing for inherited conditions
  • 2031: 30% of purebred litters genetically optimized




Reasons To Buy

Image



Scope

Image
  • Recombinetics Inc.
  • Genus plc
  • eGenesis
  • Invetx
  • AgGenetics (startups & university spinouts)
ANIMAL CRISPR THERAPEUTICS Report

ANIMAL CRISPR THERAPEUTICS Report

  1. 1. ANIMAL CRISPR THERAPEUTICS Research Report
    1. 1.1 Study Objectives
    2. 1.2 ANIMAL CRISPR THERAPEUTICS - Overview
    3. 1.3 Reason to Read This Report
    4. 1.4 Methodology and Forecast Analysis
  2. 2. ANIMAL CRISPR THERAPEUTICS Research Report - Preface
    1. 2.1 ANIMAL CRISPR THERAPEUTICS Research Report – Detailed Scope and Definitions
      1. 2.1.1 By Application
      2. 2.1.2 By Animal Type
      3. 2.1.3 By Region
    3. 3. ANIMAL CRISPR THERAPEUTICS Dynamics
    1. 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
    2. 3.2. Restraints – By Application, By Animal Type, By Country
    3. 3.3. Opportunities – By Application, By Animal Type, By Country
    4. 3.4. Trends – By Application, By Animal Type, By Country
    5. 3.5. PEST Analysis
    6. 3.6. Porters Five Rule Analysis
    7. 3.7. Company’s Share Analysis (CSA) by Region or By Country
    8. 3.8. ANIMAL CRISPR THERAPEUTICS Research Report – DROTs Impact Analysis
      4. ANIMAL CRISPR THERAPEUTICS Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
    1. 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    2. 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
    3. 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
    4. 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    5. ANIMAL CRISPR THERAPEUTICS, By Application, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
      5.1 Monogenic Disorders
    1. 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    2. 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    3. 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    4. 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      5. 5.2 Oncology
    5. 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    6. 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    7. 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    8. 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      9. 5.3 Infectious Disease
    9. 5.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    10. 5.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    11. 5.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    12. 5.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. ANIMAL CRISPR THERAPEUTICS, By Animal Type, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
      6.1 Companion Animals
    1. 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    2. 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    3. 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    4. 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      5. 6.2 Livestock
    5. 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    6. 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    7. 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    8. 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    7. ANIMAL CRISPR THERAPEUTICS Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
      7.1 North America
      1. 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.2 Europe
      1. 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.3 Asia-Pacific
      1. 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.4 Latin America
      1. 7.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.5 Middle East and Africa
      1. 7.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.6 ANIMAL CRISPR THERAPEUTICS - Opportunity Analysis Index, By Application, By Animal Type, and Region, 2024 - 2031
    8. North America ANIMAL CRISPR THERAPEUTICS Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
      8.1 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.1.1 Monogenic Disorders
      2. 8.1.2 Oncology
      3. 8.1.3 Infectious Disease
      8.2 By Animal Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.2.1 Companion Animals
      2. 8.2.2 Livestock
      8.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.3.1 United States
      2. 8.3.2 Canada
    1. 8.4 North America ANIMAL CRISPR THERAPEUTICS – Opportunity Analysis Index, By Application, By Animal Type, and Country, 2024 - 2031
    2. 8.5 Regional Trends Analysis
      3. 8.6 North America ANIMAL CRISPR THERAPEUTICS Research Report - Company Profiles
      1. 8.6.1 Company 1 (United States)
      2. 8.6.2 Company 2 (Canada)
      3. 8.6.3 Company 3 (Canada)
    9. Europe ANIMAL CRISPR THERAPEUTICS Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
      9.1 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.1.1 Monogenic Disorders
      2. 9.1.2 Oncology
      3. 9.1.3 Infectious Disease
      9.2 By Animal Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.2.1 Companion Animals
      2. 9.2.2 Livestock
      9.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.3.1 Germany
      2. 9.3.2 United Kingdom
      3. 9.3.3 France
      4. 9.3.4 Spain
      5. 9.3.5 Italy
      6. 9.3.6 Russia
    1. 9.4 Europe ANIMAL CRISPR THERAPEUTICS – Opportunity Analysis Index, By Application, By Animal Type, and Country, 2024 - 2031
    2. 9.5 Regional Trends Analysis
      3. 9.6 Europe ANIMAL CRISPR THERAPEUTICS Research Report - Company Profiles
      1. 9.6.1 Company 1 (Germany)
      2. 9.6.2 Company 2 (United Kingdom)
      3. 9.6.3 Company 3 (United Kingdom)
    10. Asia-Pacific ANIMAL CRISPR THERAPEUTICS Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
      10.1 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.1.1 Monogenic Disorders
      2. 10.1.2 Oncology
      3. 10.1.3 Infectious Disease
      10.2 By Animal Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.2.1 Companion Animals
      2. 10.2.2 Livestock
      10.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.3.1 China
      2. 10.3.2 Japan
      3. 10.3.3 India
      4. 10.3.4 South Korea
      5. 10.3.5 Australia & New Zealand
      6. 10.3.6 ASEAN
    1. 10.4 Asia-Pacific ANIMAL CRISPR THERAPEUTICS – Opportunity Analysis Index, By Application, By Animal Type, and Country, 2024 - 2031
    2. 10.5 Regional Trends Analysis
      3. 10.6 Asia-Pacific ANIMAL CRISPR THERAPEUTICS Research Report - Company Profiles
      1. 10.6.1 Company 1 (China)
      2. 10.6.2 Company 2 (Japan)
      3. 10.6.3 Company 3 (Japan)
    11. Latin America ANIMAL CRISPR THERAPEUTICS Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
      11.1 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.1.1 Monogenic Disorders
      2. 11.1.2 Oncology
      3. 11.1.3 Infectious Disease
      11.2 By Animal Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.2.1 Companion Animals
      2. 11.2.2 Livestock
      11.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.3.1 Brazil
      2. 11.3.2 Mexico
      3. 11.3.3 Argentina
      4. 11.3.4 Peru
      5. 11.3.5 Colombia
      6. 11.3.6 Rest of Latin America
    1. 11.4 Latin America ANIMAL CRISPR THERAPEUTICS – Opportunity Analysis Index, By Application, By Animal Type, and Country, 2024 - 2031
    2. 11.5 Regional Trends Analysis
      3. 11.6 Latin America ANIMAL CRISPR THERAPEUTICS Research Report - Company Profiles
      1. 11.6.1 Company 1 (Brazil)
      2. 11.6.2 Company 2 (Mexico)
      3. 11.6.3 Company 3 (Mexico)
    12. Middle East and Africa ANIMAL CRISPR THERAPEUTICS Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
      12.1 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.1.1 Monogenic Disorders
      2. 12.1.2 Oncology
      3. 12.1.3 Infectious Disease
      12.2 By Animal Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.2.1 Companion Animals
      2. 12.2.2 Livestock
      12.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.3.1 Saudi Arabia
      2. 12.3.2 UAE
      3. 12.3.3 South Africa
      4. 12.3.4 Egypt
      5. 12.3.5 Israel
      6. 12.3.6 Rest of Middle East and Africa
    1. 12.4 Middle East and Africa ANIMAL CRISPR THERAPEUTICS – Opportunity Analysis Index, By Application, By Animal Type, and Country, 2024 - 2031
    2. 12.5 Regional Trends Analysis
      3. 12.6 Middle East and Africa ANIMAL CRISPR THERAPEUTICS Research Report - Company Profiles
      1. 12.6.1 Company 1 (Saudi Arabia)
      2. 12.6.2 Company 2 (UAE)
      3. 12.6.3 Company 3 (UAE)
    13. Competition Landscape
    1. 13.1 Strategic Dashboard of Top Market Players
      2. 13.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
      1. 13.2.1 Genus PLC
      2. 13.2.2 Recombinetics
      3. 13.2.3 Tropic Biosciences
      4. 13.2.4 eGenesis
      5. 13.2.5 Precision Biosciences
      6. 13.2.6 CRISPR Therapeutics
      7. 13.2.7 Intellia Therapeutics
      8. 13.2.8 Editas Medicine
      9. 13.2.9 Caribou Biosciences
      10. 13.2.10 Sangamo Therapeutics
      11. 13.2.11 AgBiTech
      12. 13.2.12 Inari Agriculture
      13. 13.2.13 Inscripta
      14. 13.2.14 ToolGen
      15. 13.2.15 LogicBio Therapeutics.
  1. 14. Data Collection Method and Research Approach
  1. 15. Principal Presumptions and Acronyms